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CASE REPORT

Proptosis of Eye: An Atypical Presentation of Prostatic Malignancy
ABSTRACT

Amna Amjad, Asif Husain Osmani and Ghulam Haider

Orbital metastasis is a rare occurrence found only in about 3 - 10% of all prostate cancers. A 72 years male presented
with proptosis of the left eye associated with pain, blurred vision and frequent headaches for the past 8 months. Past
medical history had symptoms of bladder outflow obstruction for 3 years. MRI brain and orbit with contrast was consistent
with a large soft tissue mass in the left frontal region. The mass was surgically excised in order to achieve palliation.
Histopathology revealed poorly differentiated malignant neoplasm with immunohistochemistry favoring metastatic prostate
carcinoma. Postoperative radiotherapy was administered with a palliative intent. CT scan identified an enlarged prostate
with a nodular lesion, abdominal lymphadenopathy and soft tissue density lesion in the apical segment of left lung. Serum
PSA level was 149 µg/L. Bone scan was also consistent with metastatic disease.
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INTRODUCTION

Prostate cancer is the most common non-cutaneous
cancer in men and the second leading cause of cancer
death in USA.1 The incidence of prostate cancer is rising
rapidly in most countries including Asian countries.2 The
most common sites of metastases are bone, lung and
liver.3 Orbital metastasis is a rare occurrence found only
in about 3 - 10% of all prostate cancers. Its metastasis
to the brain has an estimated autopsy incidence of
0.64%.4 Two theories have been postulated about the
mechanism/pathway of brain metastasis. One theory
states that intracranial metastasis could be a result of
extension from adjacent metastatic foci, for example the
bone, dura matter or lung. The other theory is that there
is direct access through the paravertebral venous
plexus, thus avoiding bone and viscera.4,5
The authors present an unusual case of a patient with
proptosis as an index sign of prostate malignancy.

CASE REPORT

A 72 years male presented with proptosis of the left eye
associated with pain, blurred vision and frequent
headaches which was progressive in nature for the past
8 months. Past medical history was consistent with
bladder outflow obstruction since 3 years. MRI brain and
orbit with gadolinium was done which revealed a large
soft tissue mass measuring 7.5 x 4.0 cm in the left frontal
region involving the skull vault and extraclavarial region.
Intracranial infiltration was also seen. The mass was
occupying the left side of the orbit, obscuring the
lacrimal gland, recti muscles abducting the eyeball.
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Figure 1: MRI brain and orbit: A large soft tissue mass in the left frontal
region involving the skull vault and extraclavarial region with intracranial
extension.The mass was occupying the left side of the orbit abducting the
eyeball.

However, no infiltration was found in bulbus occuli.
There was no evidence of haemorrhage or infarction in
the brain (Figure 1).

With the intent of preserving the patient's sight, surgery
was performed. The intracranial mass was removed in
order to achieve palliation. Histopathology of the
specimen revealed poorly differentiated malignant
neoplasm favouring metastatic carcinoma. Immunohistochemistry showed positivity for cytokeratin
AE1/AE3 and CD 10. Cytokeratin CAM 5.2 was diffuse
strong positive. LCA, Desmin, Neurofilament, CD 138,
Synaptophysin, Cytokeratin 7, Cytokeratin 20, p63,
GFAP and Vimentin were found to be negative. EMA
stain was non-contributory. Postoperative radiotherapy
was administered with a palliative intent. Primary site of
the tumor was not discernible without clinical correlation.
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CT chest, abdomen and pelvis identified an enlarged
prostate with a nodular lesion. Left pelvic, para aortic
and mediastinal lymphadenopathy was also seen. A soft
tissue density lesion was found in the left lung apex,
involving the pleura. Serum PSA level was 149 µg/L.
Bone scan showed increased tracer uptake involving
the superior margin of left orbit with photon deficient
area involving frontal bone. Focal areas of increased
tracer uptake were noted over left sided 3rd rib, right
sided 5th rib anteriorly and trochanteric region left
femur. Hormonal treatment with androgen deprivation
therapy along with intravenous bisphosphonates was
commenced later.

DISCUSSION

Metastasis from primary prostate cancer to the brain is a
rare and terminal event with an expected survival of less
than one year. Death frequently occurs due to advanced
systemic disease. Most patients with brain metastasis
have a solitary lesion, although two or more lesions are
also found.4 Metastasis are more commonly from small
cell and primary transitional cell carcinoma of the
prostate as compared to adenocarcinoma of prostate.6
Orbital or ocular metastasis is reported in 2 - 5% of all
cancer patients, usually in the setting of diffuse
metastatic disease. In 25% of the cases, it is the first
sign of malignancy.3

Clinical presentations are commonly non-focal and
included cognitive changes and headaches, possibly
related to increased intracranial pressure or diffuse
cortical dysfunction. Many patients with intracranial
metastasis were asymptomatic when alive, and their
cerebral disease was discovered only retrospectively at
autopsy.4,6 The clinical presentation of metastases to the
orbital region depends on the structures affected. Pain,
diplopia and decreased visual acuity may be present if
the orbital bone, soft tissue or globe is affected
respectively. These symptoms may progress over weeks
to months.7 The role of Prostate Specific Antigen (PSA)
in the early detection of brain metastases from prostate
carcinoma is unclear. Due to the rarity of brain
metastasis CT or MRI is not indicated for raising PSA
levels, which should be used instead if there are
neurological signs and symptoms.6
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Treatments available for intracranial metastasis include
neurosurgery, external beam radiation and hormonal
manipulation. Untreated, these patients have a grim
survival of few months.4 Surgical removal of the lesion
followed by whole brain radiotherapy has shown in
studies an estimated survival of approximately
9 months.5 In another study, surgery plus radiation
showed a mean survival of 16 months as compared to 6
months for patients receiving radiation alone.8
Therefore, for solitary lesions, recommended approach
is surgery followed by whole brain radiotherapy. It has
also shown improved quality of life and duration of
survival more than either modality alone. Treatment with
hormonal agents with anti-androgens and LHRH agonist
have shown improvement clinically and marked
reduction in PSA levels.9
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